2017

Communiqué from the universities and research centres of Catalonia

Leave a Comment / Uncategorised / By

Today, the highest representatives of the universities and research centres of Catalonia (60 institutions, representing around 90% of the university and research community) have met to assess the current situation in Catalonia resulting from the actions of the Spanish Government over the last few days. The meeting was also attended by representatives of the trade […]

Communiqué from the universities and research centres of Catalonia Read More »

A group of lymphangioleiomyomatosis (LAM) patients attend a talk on the disease and advances

Leave a Comment / Hereditary cancer  / By

David J. Kwiatkowski, a professor of medicine at Harvard University and an oncologist specializing in thoracic oncology at Dana-Farber Cancer Institute in Boston, was responsible for explaining the advances in genetics and clinical trials being conducted to combat the disease What is LAM?

A group of lymphangioleiomyomatosis (LAM) patients attend a talk on the disease and advances Read More »

IDIBELL joins the Barcelona Bioinformatics Association

Leave a Comment / Uncategorised / By

The Bellvitge Biomedical Research Institute (IDIBELL) has officially joined the Bioinformatics Barcelona Association (BIB), a non-profit organization focused on the development of the field of bioinformatics in Catalonia. Established in 2015, the BIB currently comprises 53 major institutions related to the bioinformatics sector – universities, research centers, hospitals, major scientific infrastructures, companies and other partners.

IDIBELL joins the Barcelona Bioinformatics Association Read More »

Dr. Manel Esteller receives the Falcó Carlemany Award

Leave a Comment / Uncategorised / By

Manel Esteller, director of the epigenetics and cancer biology program at IDIBELL, ICREA researcher and professor at the University of Barcelona has been awarded the Falcó Carlemany Award for the social impact of his cancer research. The Falcó Carlemany Award is awarded to a person or entity for their contributions to relevant, high-impact social projects.

Dr. Manel Esteller receives the Falcó Carlemany Award Read More »

Nova eina d’anàlisi per a predir la resposta al tractament preoperatori en càncer de recte

Leave a Comment / Tumor and stromal chemoresistance  / By

Investigadors del Programa Contra la Resistència Terapèutica del Càncer (ProCURE), de l’Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) i de l’Institut Català d’Oncologia (ICO) han desenvolupat una nova eina que permet establir la probabilitat de resposta al tractament preoperatori en tumors de recte localment avançats. Predir quins pacients no respondran al tractament pot ajudar a evitar

Nova eina d’anàlisi per a predir la resposta al tractament preoperatori en càncer de recte Read More »

New epigenomic strategies in the clinical management of cancer of unknown primary

Leave a Comment / Uncategorised / By

The invention of the EPICUP® epigenetic test last year allowed physicians to elucidate what type of primary tumor had metastasized in patients with Cancer of Unknown Primary (CUP). Today, an article published in Nature Reviews Clinical Oncology by Dr. Manel Esteller, coordinator of the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute

New epigenomic strategies in the clinical management of cancer of unknown primary Read More »

A personalized treatment with metabolic therapy improves the motor and communication skills of a patient with atypical Rett syndrome

Leave a Comment / Cellular and Molecular Neurobiology , Neuropharmacology and pain  / By

Administration of the amino acid D-serine, a dietary supplement, contributes to the improvement of the cognitive and motor capacity of a patient with a mutation that affects glutamate receptors A promising treatment with no side effects Towards “express personalization”

A personalized treatment with metabolic therapy improves the motor and communication skills of a patient with atypical Rett syndrome Read More »

A new ribosomal biogenesis regulation point to treat cancer and 5q- syndrome

Leave a Comment / Cancer Metabolism / By

Researchers in the Oncobell program at the Bellvitge Biomedical Research Institute (IDIBELL) – Catalan Institute of Oncology (ICO) have unveiled a new role for free 40S ribosomes as guardians of genetic information required to synthesize themselves. This mechanism, which relies on a complex of free 40S ribosomes and the RNA binding protein LARP1, is independent

A new ribosomal biogenesis regulation point to treat cancer and 5q- syndrome Read More »

Scroll to Top